WARNING: DILAUDID ORAL LIQUID AND DILAUDID TABLETS CONTAIN HYDROMORPHONE, WHICH IS A POTENT SCHEDULE II CONTROLLED OPIOID AGONIST. SCHEDULE II OPIOID AGONISTS, INCLUDING MORPHINE, OXYMORPHONE, OXYCODONE, FENTANYL, AND METHADONE, HAVE THE HIGHEST POTENTIAL FOR ABUSE AND RISK OF PRODUCING RESPIRATORY DEPRESSION. ALCOHOL, OTHER OPIOIDS AND CENTRAL NERVOUS SYSTEM DEPRESSANTS (SEDATIVE-HYPNOTICS) POTENTIATE THE RESPIRATORY DEPRESSANT EFFECTS OF HYDROMORPHONE, INCREASING THE RISK OF RESPIRATORY DEPRESSION THAT MIGHT RESULT IN DEATH.

DESCRIPTION

<table>
<thead>
<tr>
<th>#</th>
<th>Strength</th>
<th>Form</th>
<th>Proprietary name:</th>
<th>Established name:</th>
<th>Active ingredients (moiety):</th>
<th>Inactive ingredients</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>5 MILLIGRAM</td>
<td>LIQUID (C42953)</td>
<td>DILAUDID ORAL LIQUID</td>
<td>hydromorphone hydrochloride</td>
<td>hydromorphone hydrochloride (hydromorphone)</td>
<td>purified water, methylparaben, propylparaben, sucrose, glycerin, sodium metabisulfite</td>
</tr>
<tr>
<td>2</td>
<td>2 MILLIGRAM</td>
<td>TABLET (C42998)</td>
<td>DILAUDID TABLETS</td>
<td>hydromorphone hydrochloride</td>
<td>hydromorphone hydrochloride (hydromorphone)</td>
<td>D&amp;C red #30 Lake dye, D&amp;C yellow #10 Lake dye, lactose, magnesium stearate, sodium metabisulfite</td>
</tr>
<tr>
<td>3</td>
<td>4 MILLIGRAM</td>
<td>TABLET (C42998)</td>
<td></td>
<td></td>
<td></td>
<td>D&amp;C yellow #10 Lake dye, lactose, magnesium stearate, sodium metabisulfite</td>
</tr>
<tr>
<td>4</td>
<td>8 MILLIGRAM</td>
<td>TABLET (C42998)</td>
<td></td>
<td></td>
<td></td>
<td>lactose anhydrous, magnesium stearate, sodium metabisulfite</td>
</tr>
</tbody>
</table>

DILAUDID (hydromorphone hydrochloride), a hydrogenated ketone of morphine, is an opioid analgesic.

The chemical name of DILAUDID (hydromorphone hydrochloride) is 4,5α-epoxy-3-hydroxy-17-methylmorphinan-6-one hydrochloride. The structural formula is:
Each 5 mL (1 teaspoon) of DILAUDID ORAL LIQUID contains 5 mg of hydromorphone hydrochloride. In addition, other ingredients include purified water, methylparaben, propylparaben, sucrose, and glycerin. DILAUDID ORAL LIQUID may contain traces of sodium metabisulfite.

Color Coded Tablets (for oral administration) contain:

2 mg hydromorphone hydrochloride (orange tablet) and D&C red #30 Lake dye, D&C yellow #10 Lake dye, lactose, and magnesium stearate. DILAUDID 2 mg TABLET may contain traces of sodium metabisulfite.

4 mg hydromorphone hydrochloride (yellow tablet) and D&C yellow #10 Lake dye, lactose, and magnesium stearate. DILAUDID 4 mg TABLET may contain traces of sodium metabisulfite.

8 mg hydromorphone hydrochloride (white tablet) and lactose anhydrous, and magnesium stearate. DILAUDID 8 mg TABLET may contain traces of sodium metabisulfite.

**CLINICAL PHARMACOLOGY**

Hydromorphone hydrochloride is a pure opioid agonist with the principal therapeutic activity of analgesia. A significant feature of the analgesia is that it can occur without loss of consciousness. Opioid analgesics also suppress the cough reflex and may cause respiratory depression, mood changes, mental clouding, euphoria, dysphoria, nausea, vomiting and electroencephalographic changes. Many of the effects described below are common to this class of mu-opioid agonist analgesics which includes morphine, oxycodone, hydrocodone, codeine and fentanyl. In some instances, data may not exist to distinguish the effects of DILAUDID ORAL LIQUID and DILAUDID TABLETS from those observed with other opioid analgesics. However, in the absence of data to the contrary, it is assumed that DILAUDID ORAL LIQUID and DILAUDID TABLETS would possess all the actions of mu-agonist opioids.
Central Nervous System

The precise mode of analgesic action of opioid analgesics is unknown. However, specific CNS opiate receptors have been identified. Opioids are believed to express their pharmacological effects by combining with these receptors.

Hydromorphone depresses the cough reflex by direct effect on the cough center in the medulla.

Hydromorphone depresses the respiratory reflex by a direct effect on brain stem respiratory centers. The mechanism of respiratory depression also involves a reduction in the responsiveness of the brain stem respiratory centers to increases in carbon dioxide tension.

Hydromorphone causes miosis. Pinpoint pupils are a common sign of opioid overdose but are not pathognomonic (e.g., pontine lesions of hemorrhagic or ischemic origin may produce similar findings). Marked mydriasis rather than miosis may be seen with hypoxia in the setting of DILAUDID overdose.

Gastrointestinal Tract and Other Smooth Muscle

Gastric, biliary and pancreatic secretions are decreased by opioids such as hydromorphone. Hydromorphone causes a reduction in motility associated with an increase in tone in the gastric antrum and duodenum. Digestion of food in the small intestine is delayed and propulsive contractions are decreased. Propulsive peristaltic waves in the colon are decreased, and tone may be increased to the point of spasm. The end result is constipation. Hydromorphone can cause a marked increase in biliary tract pressure as a result of spasm of the sphincter of Oddi.

Cardiovascular System

Hydromorphone may produce hypotension as a result of either peripheral vasodilation or release of histamine, or both. Other manifestations of histamine release and/or peripheral vasodilation may include pruritus, flushing, and red eyes.

Pharmacokinetics and Metabolism

The analgesic activity of DILAUDID (hydromorphone hydrochloride) is due to the parent drug, hydromorphone. Hydromorphone is rapidly absorbed from the gastrointestinal tract after oral administration and undergoes extensive first-pass metabolism. Exposure of hydromorphone (C_max and AUC_{0-24}) is dose-proportional at a dose range of 2 and 8 mg. In vivo bioavailability following single-dose administration of the 8 mg tablet is approximately 24% (coefficient of variation 21%). Bioequivalence between the DILAUDID 8 mg TABLET and an equivalent dose of DILAUDID ORAL LIQUID has been demonstrated.

Absorption

After oral administration of DILAUDID 8 mg liquid or tablets, peak plasma hydromorphone concentrations are generally attained within ½ to 1-hour.

<table>
<thead>
<tr>
<th>Dosage Form</th>
<th>Mean (%cv) C_max (ng)</th>
<th>Mean (%cv) T_max (hrs)</th>
<th>Mean (%cv) AUC (ng*hr/mL)</th>
<th>Mean (%cv) T_{1/2} (hrs)</th>
</tr>
</thead>
<tbody>
<tr>
<td>8 mg Tablet</td>
<td>5.5 (33%)</td>
<td>0.74 (34%)</td>
<td>23.7 (28%)</td>
<td>2.6 (18%)</td>
</tr>
<tr>
<td>8 mg Oral Liquid</td>
<td>5.7 (31%)</td>
<td>0.73 (71%)</td>
<td>24.6 (29%)</td>
<td>2.8 (20%)</td>
</tr>
</tbody>
</table>
**Food Effects**

In a study conducted with a single 8 mg dose of hydromorphone (2 mg DILAUDID® IR tablets), food lowered C\textsubscript{max} by 25%, prolonged T\textsubscript{max} by 0.8 hour, and increased AUC by 35%. The effects may not be clinically relevant.

**Distribution**

At therapeutic plasma levels, hydromorphone is approximately 8-19% bound to plasma proteins. After an intravenous bolus dose, the steady state of volume distribution [mean (%cv)] is 302.9 (32%) liters.

**Metabolism**

Hydromorphone is extensively metabolized via glucuronidation in the liver, with greater than 95% of the dose metabolized to hydromorphone-3-glucuronide along with minor amounts of 6-hydroxy reduction metabolites.

**Elimination**

Only a small amount of the hydromorphone dose is excreted unchanged in the urine. Most of the dose is excreted as hydromorphone-3-glucuronide along with minor amounts of 6-hydroxy reduction metabolites. The systemic clearance is approximately 1.96 (20%) liters/minute. The terminal elimination half-life of hydromorphone after an intravenous dose is about 2.3 hours.

**Special Populations**

**Hepatic Impairment**

After oral administration of hydromorphone at a single 4 mg dose (2 mg Dilaudid IR Tablets), mean exposure to hydromorphone (C\textsubscript{max} and AUC\textsubscript{\textsuperscript{\infty}}) is increased 4-fold in patients with moderate (Child-Pugh Group B) hepatic impairment compared with subjects with normal hepatic function. Due to increased exposure of hydromorphone, patients with moderate hepatic impairment should be started at a lower dose and closely monitored during dose titration. Pharmacokinetics of hydromorphone in severe hepatic impairment patients has not been studied. Further increase in C\textsubscript{max} and AUC of hydromorphone in this group is expected. As such, starting dose should be even more conservative. Use of oral liquid is recommended to adjust the dose (see DOSAGE AND ADMINISTRATION).

**Renal Impairment**

After oral administration of hydromorphone at a single 4 mg dose (2 mg Dilaudid IR Tablets), exposure to hydromorphone (C\textsubscript{max} and AUC\textsubscript{0-48}) is increased in patients with impaired renal function by 2-fold in moderate (CL\textsubscript{cr} = 40 - 60 mL/min) and 3-fold in severe (CL\textsubscript{cr} < 30 mL/min) renal impairment compared with normal subjects (CL\textsubscript{cr} > 80 mL/min). In addition, in patients with severe renal impairment hydromorphone appeared to be more slowly eliminated with longer terminal elimination half-life (40 hr) compared to patients with normal renal function (15 hr). Patients with moderate renal impairment should be started on a lower dose. Starting doses for patients with severe renal impairment should be even lower. Patients with renal impairment should be closely monitored during dose titration. Use of oral liquid is recommended to adjust the dose (see DOSAGE AND ADMINISTRATION).
Pediatrics
Pharmacokinetics of hydromorphone have not been evaluated in children.

Geriatric
Age has no effect on the pharmacokinetics of hydromorphone.

Gender
Gender has little effect on the pharmacokinetics of hydromorphone. Females appear to have higher $C_{\text{max}}$ (25%) than males with comparable $\text{AUC}_{0-24}$ values. The difference observed in $C_{\text{max}}$ may not be clinically relevant.

Pregnancy and Nursing Mothers
Hydromorphone crosses the placenta. Hydromorphone is also found in low levels in breast milk, and may cause respiratory compromise in newborns when administered during labor or delivery.

CLINICAL TRIALS
Analgesic effects of single doses of DILAUDID ORAL LIQUID administered to patients with post-surgical pain have been studied in double-blind controlled trials. In one study, both 5 mg and 10 mg of DILAUDID ORAL LIQUID provided significantly more analgesia than placebo. In another trial, 5 mg and 10 mg of DILAUDID ORAL LIQUID were compared to 30 mg and 60 mg of morphine sulfate oral liquid. The pain relief provided by 5 mg and 10 mg DILAUDID ORAL LIQUID was comparable to 30 mg and 60 mg oral morphine sulfate, respectively.

INDICATIONS AND USAGE
DILAUDID ORAL LIQUID and DILAUDID TABLETS are indicated for the management of pain in patients where an opioid analgesic is appropriate.

CONTRAINDICATIONS
DILAUDID ORAL LIQUID and DILAUDID TABLETS are contraindicated in: patients with known hypersensitivity to hydromorphone, patients with respiratory depression in the absence of resuscitative equipment, and in patients with status asthmaticus. DILAUDID ORAL LIQUID and DILAUDID TABLETS are also contraindicated for use in obstetrical analgesia.

WARNINGS
Respiratory Depression
Respiratory depression is the chief hazard of DILAUDID ORAL LIQUID and DILAUDID TABLETS. Respiratory depression is more likely to occur in the elderly, in the debilitated, and in those suffering from conditions accompanied by hypoxia or hypercapnia when even moderate therapeutic doses may dangerously decrease pulmonary ventilation.

DILAUDID ORAL LIQUID and DILAUDID TABLETS should be used with extreme caution in patients with chronic obstructive pulmonary disease or cor pulmonale, patients having a
substantially decreased respiratory reserve, hypoxia, hypercapnia, or in patients with preexisting respiratory depression. In such patients even usual therapeutic doses of opioid analgesics may decrease respiratory drive while simultaneously increasing airway resistance to the point of apnea.

**DILAUDID ORAL LIQUID and DILAUDID TABLETS** contain hydromorphone, which is a potent Schedule II controlled opioid agonist. Schedule II opioid agonists, including morphine, oxymorphone, oxycodone, fentanyl, and methadone, have the highest potential for abuse and risk of producing respiratory depression. Alcohol, other opioids and central nervous system depressants (sedative-hypnotics) potentiate the respiratory depressant effects of hydromorphone, increasing the risk of respiratory depression that might result in death.

**Misuse, Abuse, and Diversion of Opioids**

Hydromorphone is an opioid agonist of the morphine-type. Such drugs are sought by drug abusers and people with addiction disorders and are subject to criminal diversion.

DILAUDID can be abused in a manner similar to other opioid agonists, legal or illicit. This should be considered when prescribing or dispensing DILAUDID in situations where the physician or pharmacist is concerned about an increased risk of misuse, abuse, or diversion. Prescribers should monitor all patients receiving opioids for signs of abuse, misuse, and addiction. Furthermore, patients should be assessed for their potential for opioid abuse prior to being prescribed opioid therapy. Persons at increased risk for opioid abuse include those with a personal or family history of substance abuse (including drug or alcohol abuse) or mental illness (e.g., depression). Opioids may still be appropriate for use in these patients, however, they will require intensive monitoring for signs of abuse

DILAUDID has been reported as being abused by crushing, chewing, snorting, or injecting the dissolved product. These practices pose a significant risk to the abuser that could result in overdose or death (see **WARNINGS** and **DRUG ABUSE AND DEPENDENCE**).

Concerns about abuse, addiction, and diversion should not prevent the proper management of pain.

Healthcare professionals should contact their State Professional Licensing Board or State Controlled Substances Authority for information on how to prevent and detect abuse or diversion of this product.

**Interactions with Alcohol and Drugs of Abuse**

Hydromorphone may be expected to have additive effects when used in conjunction with alcohol, other opioids, or illicit drugs that cause central nervous system depression.

**Neonatal Withdrawal Syndrome**

Infants born to mothers physically dependent on DILAUDID will also be physically dependent and may exhibit respiratory difficulties and withdrawal symptoms (see **DRUG ABUSE AND DEPENDENCE**).

**Head Injury and Increased Intracranial Pressure**

The respiratory depressant effects of DILAUDID ORAL LIQUID and DILAUDID TABLETS with carbon dioxide retention and secondary elevation of cerebrospinal fluid pressure may be markedly exaggerated in the presence of head injury, other intracranial lesions, or preexisting increase in intracranial pressure. Opioid analgesics including DILAUDID ORAL
LIQUID and DILAUDID TABLETS (hydromorphone hydrochloride) may produce effects on pupillary response and consciousness which can obscure the clinical course and neurologic signs of further increase in intracranial pressure in patients with head injuries.

**Hypotensive Effect**

Opioid analgesics, including DILAUDID ORAL LIQUID and DILAUDID TABLETS, may cause severe hypotension in an individual whose ability to maintain blood pressure has already been compromised by a depleted blood volume, or a concurrent administration of drugs such as phenothiazines or general anesthetics (see **PRECAUTIONS - Drug Interactions**). Therefore, DILAUDID ORAL LIQUID and DILAUDID TABLETS should be administered with caution to patients in circulatory shock, since vasodilation produced by the drug may further reduce cardiac output and blood pressure.

**Sulfites**

Contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in nonasthmatic people.

**PRECAUTIONS**

**Special Risk Patients**

DILAUDID ORAL LIQUID and DILAUDID TABLETS should be given with caution and the initial dose should be reduced in the elderly or debilitated and those with severe impairment of hepatic, pulmonary or renal functions; myxedema or hypothyroidism; adrenocortical insufficiency (e.g., Addison's Disease); CNS depression or coma; toxic psychoses; prostatic hypertrophy or urethral stricture; gall bladder disease; acute alcoholism; delirium tremens; kyphoscoliosis or following gastrointestinal surgery.

The administration of opioid analgesics including DILAUDID ORAL LIQUID and DILAUDID TABLETS may obscure the diagnoses or clinical course in patients with acute abdominal conditions and may aggravate preexisting convulsions in patients with convulsive disorders.

Reports of mild to severe seizures and myoclonus have been reported in severely compromised patients, administered high doses of parenteral hydromorphone, for cancer and severe pain. Opioid administration at very high doses is associated with seizures and myoclonus in a variety of diseases where pain control is the primary focus.

**Use in Drug and Alcohol Dependent Patients**

DILAUDID should be used with caution in patients with alcoholism and other drug dependencies due to the increased frequency of opioid tolerance, dependence, and the risk of addiction observed in these patient populations. Abuse of DILAUDID in combination with other CNS depressant drugs can result in serious risk to the patient.

Hydromorphone is an opioid with no approved use in the management of addictive disorders.

**Use in Ambulatory Patients**
DILAUDID ORAL LIQUID and DILAUDID TABLETS may impair mental and/or physical ability required for the performance of potentially hazardous tasks (e.g. driving, operating machinery). Patients should be cautioned accordingly. DILAUDID may produce orthostatic hypotension in ambulatory patients.

Use in Biliary Tract Disease

Opioid analgesics, including DILAUDID ORAL LIQUID and DILAUDID TABLETS, should also be used with caution in patients about to undergo surgery of the biliary tract since it may cause spasm of the sphincter of Oddi.

Tolerance and Physical Dependence

Tolerance is the need for increasing doses of opioids to maintain a defined effect such as analgesia (in the absence of disease progression or other external factors). Physical dependence is manifested by withdrawal symptoms after abrupt discontinuation of a drug or upon administration of an antagonist. Physical dependence and tolerance are not unusual during chronic opioid therapy.

The opioid abstinence or withdrawal syndrome is characterized by some or all of the following: restlessness, lacrimation, rhinorrhea, yawning, perspiration, chills, myalgia, mydriasis. Other symptoms also may develop, including: irritability, anxiety, backache, joint pain, weakness, abdominal cramps, insomnia, nausea, anorexia, vomiting, diarrhea, or increased blood pressure, respiratory rate, or heart rate.

In general, opioids used regularly should not be abruptly discontinued.

Information for Patients/Caregivers

Patients receiving DILAUDID (hydromorphone hydrochloride) ORAL LIQUID or DILAUDID TABLETS or their caregivers should be given the following information by the physician, nurse, or pharmacist:

1. Patients should be aware that DILAUDID tablets contain hydromorphone, which is a morphine-like substance and which could cause severe adverse effects including respiratory depression and even death if not taken according to the prescriber’s directions.
2. Patients should be advised to report pain and adverse experiences occurring during therapy. Individualization of dosage is essential to make optimal use of this medication.
3. Patients should be advised not to adjust the dose of DILAUDID without consulting the prescribing professional.
4. Patients should be advised that DILAUDID may impair mental and/or physical ability required for the performance of potentially hazardous tasks (e.g., driving, operating heavy machinery).
5. Patients should not combine DILAUDID with alcohol or other central nervous system depressants (sleep aids, tranquilizers) except by the orders of the prescribing physician, because dangerous additive effects may occur, resulting in serious injury or death.
6. Women of childbearing potential who become, or are planning to become pregnant should be advised to consult their physician regarding the effects of analgesics and other drug use during pregnancy on themselves and their unborn child.
7. Patients should be advised that DILAUDID is a potential drug of abuse. They should protect it from theft, and it should never be given to anyone other than the individual for whom it was prescribed.
8. Patients should be advised that if they have been receiving treatment with DILAUDID for more than a few weeks and cessation of therapy is indicated, it may be appropriate to taper the DILAUDID dose, rather than abruptly discontinue it, due to the risk of precipitating withdrawal symptoms. Their physician can provide a dose schedule to accomplish a gradual discontinuation of the medication.

9. Patients should be instructed to keep DILAUDID in a secure place out of the reach of children. When DILAUDID is no longer needed, the unused tablets should be destroyed by flushing down the toilet.

**Drug Interactions**

Drug Interactions with Other CNS Depressants

The concomitant use of other central nervous system depressants including sedatives or hypnotics, general anesthetics, phenothiazines, tranquilizers and alcohol may produce additive depressant effects. Respiratory depression, hypotension and profound sedation or coma may occur. When such combined therapy is contemplated, the dose of one or both agents should be reduced. DILAUDID should not be taken with alcohol. Opioid analgesics, including DILAUDID ORAL LIQUID and DILAUDID TABLETS, may enhance the action of neuromuscular blocking agents and produce an excessive degree of respiratory depression.

Interactions with Mixed Agonist/Antagonist Opioid Analgesics

Agonist/antagonist analgesics (i.e., pentazocine, nalbuphine, butorphanol, and buprenorphine) should be administered with caution to a patient who has received or is receiving a course of therapy with a pure opioid agonist analgesic such as hydromorphone. In this situation, mixed agonist/antagonist analgesics may reduce the analgesic effect of hydromorphone and/or may precipitate withdrawal symptoms in these patients.

**Carcinogenesis, Mutagenesis, Impairment of Fertility**

No carcinogenicity studies have been conducted in animals.

Hydromorphone was not mutagenic in the in vitro Ames reverse mutation assay or the human lymphocyte chromosome aberration assay. Hydromorphone was not clastogenic in the in vivo mouse micronucleus assay.

No effects on fertility, reproductive performance, or reproductive organ morphology were observed in male or female rats given oral doses up to 7 mg/kg/day, which is equivalent to the human dose of 2.5-10 mg every 3 to 6 hours for oral liquid, and 3-fold higher than the human dose of 2-4 mg every 4 to 6 hours for the tablet on a body surface area basis.

**Pregnancy**

Pregnancy Category C

No effects on teratogenicity or embryotoxicity were observed in female rats given oral doses up to 7 mg/kg/day, which is approximately equivalent to the human dose of 2.5-10 mg every 3 to 6 hours for oral liquid, and 3-fold higher than the human dose of 2-4 mg every 4 to 6 hours for the tablet on a body surface area basis. Hydromorphone produced skull malformations (exencephaly and cranioschisis) in Syrian hamsters given oral doses up to 20 mg/kg during the peak of organogenesis (gestation days 8-9). The skull malformations were observed at doses approximately 2-fold higher the human dose of
2.5-10 mg every 3 to 6 hours for oral liquid, and 7-fold higher than the human dose of 2-4 mg every 4 to 6 hours for the tablet on a body surface area basis. There are no adequate and well-controlled studies of DILAUDID in pregnant women.

Hydromorphone crosses the placenta, resulting in fetal exposure. DILAUDID ORAL LIQUID and DILAUDID TABLETS should be used in pregnant women only if the potential benefit justifies the potential risk to the fetus (see Labor and Delivery and DRUG ABUSE AND DEPENDENCE).

Nonteratogenic Effects

Babies born to mothers who have been taking opioids regularly prior to delivery will be physically dependent. The withdrawal signs include irritability and excessive crying, tremors, hyperactive reflexes, increased respiratory rate, increased stools, sneezing, yawning, vomiting, and fever. The intensity of the syndrome does not always correlate with the duration of maternal opioid use or dose. There is no consensus on the best method of managing withdrawal. Approaches to the treatment of this syndrome have included supportive care and, when indicated, drugs such as paregoric or phenobarbital.

Labor and Delivery

DILAUDID ORAL LIQUID and DILAUDID TABLETS are contraindicated in Labor and Delivery (see CONTRAINDICATIONS).

Nursing Mothers

Low levels of opioid analgesics have been detected in human milk. As a general rule, nursing should not be undertaken while a patient is receiving DILAUDID ORAL LIQUID and DILAUDID TABLETS since it, and other drugs in this class, may be excreted in the milk.

Pediatric Use

Safety and effectiveness in children have not been established.

Geriatric Use

Clinical studies of DILAUDID did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy (see INDIVIDUALIZATION OF DOSAGES and PRECAUTIONS).

ADVERSE REACTIONS

The major hazards of DILAUDID ORAL LIQUID and DILAUDID TABLETS include respiratory depression and apnea. To a lesser degree, circulatory depression, respiratory arrest, shock and cardiac arrest have occurred.

The most frequently observed adverse effects are light-headedness, dizziness, sedation, nausea, vomiting, sweating, flushing, dysphoria, euphoria, dry mouth, and pruritus. These effects seem to be more prominent in ambulatory patients and in those not experiencing severe pain.
Less Frequently Observed Adverse Reactions

General and CNS
Weakness, headache, agitation, tremor, uncoordinated muscle movements, alterations of mood (nervousness, apprehension, depression, floating feelings, dreams), muscle rigidity, paresthesia, muscle tremor, blurred vision, nystagmus, diplopia and miosis, transient hallucinations and disorientation, visual disturbances, insomnia, increased intracranial pressure

Cardiovascular
Flushing of the face, chills, tachycardia, bradycardia, palpitation, faintness, syncope, hypotension, hypertension

Respiratory
Bronchospasm and laryngospasm

Gastrointestinal
Constipation, biliary tract spasm, ileus, anorexia, diarrhea, cramps, taste alteration

Genitourinary
Urinary retention or hesitancy, antidiuretic effects

Dermatologic
Urticaria, other skin rashes, diaphoresis

OVERDOSAGE
Serious overdosage with DILAUDID ORAL LIQUID and DILAUDID TABLETS is characterized by respiratory depression, somnolence progressing to stupor or coma, skeletal muscle flaccidity, cold and clammy skin, constricted pupils, and sometimes bradycardia and hypotension. In serious overdosage, particularly following intravenous injection, apnea, circulatory collapse, cardiac arrest and death may occur.

In the treatment of overdosage, primary attention should be given to the reestablishment of adequate respiratory exchange through provision of a patent airway and institution of assisted or controlled ventilation. A potentially serious oral ingestion, if recent, should be managed with gut decontamination. In unconscious patients with a secure airway, instill activated charcoal (30-100 g in adults, 1-2 g/kg in infants) via a nasogastric tube. A saline cathartic or sorbitol may be added to the first dose of activated charcoal.

Supportive measures (including oxygen, vasopressors) should be employed in the management of circulatory shock and pulmonary edema accompanying overdose as indicated. Cardiac arrest or arrhythmias may require cardiac massage or defibrillation.

The opioid antagonist, naloxone, is a specific antidote against respiratory depression which may result from overdosage, or unusual sensitivity to DILAUDID ORAL LIQUID and DILAUDID TABLETS. Therefore, an appropriate dose of this antagonist should be administered, preferably by the intravenous route, simultaneously with efforts at respiratory resuscitation. Naloxone should not be administered in the absence of clinically significant respiratory or circulatory depression. Naloxone should be administered
cautiously to persons who are known, or suspected to be physically dependent on DILAUDID ORAL LIQUID and DILAUDID TABLETS. In such cases, an abrupt or complete reversal of narcotic effects may precipitate an acute withdrawal syndrome. Since the duration of action of DILAUDID ORAL LIQUID and DILAUDID TABLETS may exceed that of the antagonist, the patient should be kept under continued surveillance; repeated doses of the antagonist may be required to maintain adequate respiration. Apply other supportive measures when indicated.

**DOSAGE AND ADMINISTRATION**

**Dilaudid Oral Liquid**

The usual adult oral dosage of DILAUDID ORAL LIQUID is one-half (2.5 mL) to two teaspoonfuls (10 mL) (2.5 mg - 10 mg) every 3 to 6 hours as directed by the clinical situation. Oral dosages higher than the usual dosages may be required in some patients.

**Dilaudid Tablets**

The usual starting dose for DILAUDID tablets is 2 mg to 4 mg, orally, every 4 to 6 hours. Appropriate use of the DILAUDID TABLETS must be decided by careful evaluation of each clinical situation.

A gradual increase in dose may be required if analgesia is inadequate, as tolerance develops, or if pain severity increases. The first sign of tolerance is usually a reduced duration of effect.

Patients with hepatic and renal impairment should be started on a lower starting dose (See CLINICAL PHARMACOLOGY - Pharmacokinetics and Metabolism).

**INDIVIDUALIZATION OF DOSAGE**

The dosage of opioid analgesics like hydromorphone hydrochloride should be individualized for any given patient, since adverse events can occur at doses that may not provide complete freedom from pain.

Safe and effective administration of opioid analgesics to patients with acute or chronic pain depends upon a comprehensive assessment of the patient. The nature of the pain (severity, frequency, etiology, and pathophysiology) as well as the concurrent medical status of the patient will affect selection of the starting dosage.

In non-opioid-tolerant patients, therapy with hydromorphone is typically initiated at an oral dose of 2-4 mg every four hours, but elderly patients may require lower doses (see PRECAUTIONS - Geriatric Use).

In patients receiving opioids, both the dose and duration of analgesia will vary substantially depending on the patient's opioid tolerance. The dose should be selected and adjusted so that at least 3-4 hours of pain relief may be achieved. In patients taking opioid analgesics, the starting dose of DILAUDID should be based on prior opioid usage. This should be done by converting the total daily usage of the previous opioid to an equivalent total daily dosage of oral DILAUDID using an equianalgesic table (see below). For opioids not in the table, first estimate the equivalent total daily dosage of oral morphine, then use the table to find the equivalent total daily dosage of DILAUDID.

Once the total daily dosage of DILAUDID has been estimated, it should be divided into the desired number of doses. Since there is individual variation in response to different opioid
drugs, only 1/2 to 2/3 of the estimated dose of DILAUDID calculated from equivalence
tables should be given for the first few doses, then increased as needed according to the
patient's response.

Since the pharmacokinetics of hydromorphone are affected in hepatic and renal
impairment with a consequent increase in exposure, patients with hepatic and renal
impairment should be started on a lower starting dose (See CLINICAL
PHARMACOLOGY - Pharmacokinetics and Metabolism).

In chronic pain, doses should be administered around-the-clock. A supplemental dose of
5-15% of the total daily usage may be administered every two hours on an "as-needed"
basis.

Periodic reassessment after the initial dosing is always required. If pain management is
not satisfactory and in the absence of significant opioid-induced adverse events, the
hydromorphone dose may be increased gradually. If excessive opioid side effects are
observed early in the dosing interval, the hydromorphone dose should be reduced. If this
results in breakthrough pain at the end of the dosing interval, the dosing interval may need
to be shortened. Dose titration should be guided more by the need for analgesia than the
absolute dose of opioid employed.

OPIOID ANALGESIC EQUIVALENTS WITH APPROXIMATELY EQUIANALGESIC
POTENCY*

<table>
<thead>
<tr>
<th>Nonproprietary (Trade) Name</th>
<th>IM or SC Dose</th>
<th>ORAL Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>Morphine sulfate</td>
<td>10 mg</td>
<td>40-60 mg</td>
</tr>
<tr>
<td>Hydromorphone HCl</td>
<td>1.3-2 mg</td>
<td>6.5-7.5 mg</td>
</tr>
<tr>
<td>(DILAUDID)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oxymorphone HCl</td>
<td>1-1.1 mg</td>
<td>6.6 mg</td>
</tr>
<tr>
<td>(Numorphan)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Levoorphanol tartrate</td>
<td>2-2.3 mg</td>
<td>4 mg</td>
</tr>
<tr>
<td>(Levo-Dromoran)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Meperidine, pethidine HCl</td>
<td>75-100 mg</td>
<td>300-400 mg</td>
</tr>
<tr>
<td>(Demerol)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Methadone HCl</td>
<td>10 mg</td>
<td>10-20 mg</td>
</tr>
<tr>
<td>(Dolophine)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Dosages, and ranges of dosages represented, are a compilation of estimated equipotent dosages from published
references comparing opioid analgesics in cancer and severe pain.

DRUG ABUSE AND DEPENDENCE

DILAUDID ORAL LIQUID and DILAUDID TABLETS contain hydromorphone, a
Schedule II controlled opioid agonist. Schedule II opioid substances which include
morphine, oxycodone, oxymorphone, fentanyl, and methadone have the highest
potential for abuse and risk of fatal overdose. Hydromorphone can be abused and
is subject to criminal diversion.

Opioid analgesics may cause psychological and physical dependence. Physical
dependence results in withdrawal symptoms in patients who abruptly discontinue
the drug. Physical dependence usually does not occur to a clinically significant
degree until after several weeks of continued opioid usage, but it may occur after as
little as a week of opioid use. Physical dependence and tolerance are separate and distinct from abuse and addiction.

Addiction is a chronic, neurobiologic disease, with genetic, psychosocial, and environmental factors influencing its development and manifestations. It is characterized by behaviors that include one or more of the following: impaired control over drug use, compulsive use, continued use despite harm, and craving. Drug addiction is a treatable disease, utilizing a multidisciplinary approach, but relapse is common.

“Drug seeking” behavior is very common in addicts and drug abusers. Drug-seeking tactics include emergency calls or visits near the end of office hours, refusal to undergo appropriate examination, testing or referral, repeated “loss” of prescriptions, tampering with, forging or counterfeiting prescriptions and reluctance to provide prior medical records or contact information for other treating physician(s). “Doctor shopping” to obtain additional prescriptions is common among drug abusers, people suffering from untreated addiction and criminals seeking drugs to sell.

Physicians should be aware that addiction may not be accompanied by concurrent tolerance and symptoms of physical dependence in all addicts. In addition, abuse of opioids can occur in the absence of addiction and is characterized by misuse for non-medical purposes, often in combination with other psychoactive substances. Since DILAUDID ORAL LIQUID and DILAUDID TABLETS may be diverted for non-medical use, careful record keeping of prescribing information, including quantity, frequency, and renewal requests is strongly advised.

Proper assessment of the patient, proper prescribing practices, periodic re-evaluation of therapy, and proper dispensing and storage are appropriate measures that help to limit abuse of opioid drugs.

DILAUDID ORAL LIQUID and DILAUDID TABLETS are intended for oral use only. Misuse or abuse of DILAUDID ORAL LIQUID and DILAUDID TABLETS pose a risk of overdose and death. This risk is increased with concurrent abuse of alcohol and other CNS depressants. Parenteral drug abuse can potentially result in local tissue necrosis, infection, pulmonary granulomas, and increased risk of endocarditis and valvular heart injury. In addition, parenteral abuse is commonly associated with transmission of infectious diseases such as hepatitis and HIV.

SAFETY AND HANDLING INSTRUCTIONS

DILAUDID ORAL LIQUID and DILAUDID TABLETS pose little risk of direct exposure to health care personnel and should be handled and disposed of prudently in accordance with hospital or institutional policy. Significant absorption from dermal exposure is unlikely; accidental dermal exposure to DILAUDID ORAL LIQUID should be treated by removal of any contaminated clothing and rinsing the affected area with cool water. Patients and their families should be instructed to flush any DILAUDID ORAL LIQUID and DILAUDID TABLETS that are no longer needed.

Access to abuseable drugs such as DILAUDID ORAL LIQUID and DILAUDID TABLETS presents an occupational hazard for addiction in the health care industry. Routine procedures for handling controlled substances developed to protect the public may not be adequate to protect health care workers. Implementation of more effective accounting procedures and measures to restrict access to drugs of this class (appropriate to the practice setting) may minimize the risk of self-administration by health care providers.
### HOW SUPPLIED

<table>
<thead>
<tr>
<th>#</th>
<th>Name</th>
<th>Strength</th>
<th>Dosage Form</th>
<th>Appearance</th>
<th>Package Type</th>
<th>Package Qty</th>
<th>NDC</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>DILAUDID</td>
<td>5 MILLIGRAM LIQUID (C42953)</td>
<td>BOTTLE (C43169)</td>
<td>473 MILLILITER</td>
<td>0074-2452-02</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>ORAL LIQUID</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>DILAUDID</td>
<td>2 MILLIGRAM TABLET (C42998)</td>
<td>BOTTLE (C43169)</td>
<td>100 TABLET</td>
<td>0074-2415-14</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>TABLETS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td>DILAUDID</td>
<td>2 MILLIGRAM TABLET (C42998)</td>
<td>BLISTER PACK (C43168)</td>
<td>25 TABLET</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>TABLETS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>DILAUDID</td>
<td>4 MILLIGRAM TABLET (C42998)</td>
<td>BOTTLE (C43169)</td>
<td>100 TABLET</td>
<td>0074-2416-14</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>TABLETS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>DILAUDID</td>
<td>4 MILLIGRAM TABLET (C42998)</td>
<td>BOTTLE (C43169)</td>
<td>500 TABLET</td>
<td>0074-2416-54</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>TABLETS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3</td>
<td>DILAUDID</td>
<td>4 MILLIGRAM TABLET (C42998)</td>
<td>BLISTER PACK (C43168)</td>
<td>25 TABLET</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>TABLETS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4</td>
<td>DILAUDID</td>
<td>8 MILLIGRAM TABLET (C42998)</td>
<td>BOTTLE (C43169)</td>
<td>100 TABLET</td>
<td>0074-2426-14</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>TABLETS</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

DILAUDID ORAL LIQUID is a clear, sweet, slightly viscous liquid. It is available in: Bottles of 1 pint (473 mL) - NDC# 0074-2452-02

DILAUDID 2 mg TABLETS are orange, debossed with the Abbott “A” logo on one side and the number 2 on the opposite side. They are available in: Bottles of 100 - NDC #0074-2415-14
Abbo-Pac® Unit Dose Packages of 100 (4x25) - NDC #0074-2415-12

DILAUDID 4 mg TABLETS are yellow, debossed with the Abbott “A” logo on one side and the number 4 on the opposite side. They are available in: Bottles of 100 - NDC #0074-2416-14.
Abbo-Pac® Unit Dose Packages of 100 (4x25) - NDC #0074-2416-12.
Bottles of 500 - NDC #0074-2416-54

DILAUDID 8 mg TABLETS are white and triangular shaped, debossed with a double Abbott “A” logo on one side and bisected and debossed with the number 8 on the opposite side. They are available in: Bottles of 100 - NDC# 0074-2426-14

**Storage**

Store at 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F). [See USP Controlled Room Temperature]. Protect from light.

A schedule **CS-II** Narcotic. DEA Order Form is Required.

©Abbott

All rights reserved.

Abbott Laboratories, North Chicago, IL 60064, U.S.A.
Dilaudid® 2mg
hydrochloride HCI

Do not accept if seal over bottle
opening is broken or missing.

Storage: Store at 25°C
(77°F); excursions permitted
to 15°C to 30°C (59°F to 86°F).
[See USP Controlled Room
Temperature]. Dispense in a
light-resistant container
as defined in the USP.

Abbott Laboratories
North Chicago, IL 60064, U.S.A.
100 TABLETS  NDC 0074-2416-14

Dilaudid® 4mg hydromorphone HCl

6033-01-140-4123
Do not accept if seal over bottle opening is broken or missing.

Usual Dose: See package insert.

Storage: Store at 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F) (See USP Controlled Room Temperature). Dispense in a

Abbott Laboratories
North Chicago, Il, 60064, U.S.A.
Dilaudid® 4mg hydromorphone HCl

Do not accept if seal near bottle opening is broken or missing. Internal (seal): This package insert.

Storage: Store at 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F) (See USP Controlled Room Temperature). Dispense in a tight, light-resistant container as defined in the USP.

Abbott Laboratories
North Chicago, IL 60064, U.S.A.

NDA 19-892
<table>
<thead>
<tr>
<th>NDC</th>
<th>Product Name</th>
<th>Material</th>
<th>Manufacturer</th>
<th>Location</th>
<th>Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>0074-2415-12</td>
<td>Dilaudid® 2mg Tablet</td>
<td>Hydrocodone HCl</td>
<td>Abbott Labs</td>
<td>Chicago, IL</td>
<td>60064</td>
</tr>
<tr>
<td>0074-2415-12</td>
<td>Dilaudid® 2mg Tablet</td>
<td>Hydrocodone HCl</td>
<td>Abbott Labs</td>
<td>Chicago, IL</td>
<td>60064</td>
</tr>
<tr>
<td>0074-2415-12</td>
<td>Dilaudid® 2mg Tablet</td>
<td>Hydrocodone HCl</td>
<td>Abbott Labs</td>
<td>Chicago, IL</td>
<td>60064</td>
</tr>
<tr>
<td>0074-2415-12</td>
<td>Dilaudid® 2mg Tablet</td>
<td>Hydrocodone HCl</td>
<td>Abbott Labs</td>
<td>Chicago, IL</td>
<td>60064</td>
</tr>
<tr>
<td>0074-2415-12</td>
<td>Dilaudid® 2mg Tablet</td>
<td>Hydrocodone HCl</td>
<td>Abbott Labs</td>
<td>Chicago, IL</td>
<td>60064</td>
</tr>
<tr>
<td>0074-2415-12</td>
<td>Dilaudid® 2mg Tablet</td>
<td>Hydrocodone HCl</td>
<td>Abbott Labs</td>
<td>Chicago, IL</td>
<td>60064</td>
</tr>
<tr>
<td>0074-2415-12</td>
<td>Dilaudid® 2mg Tablet</td>
<td>Hydrocodone HCl</td>
<td>Abbott Labs</td>
<td>Chicago, IL</td>
<td>60064</td>
</tr>
<tr>
<td>0074-2415-12</td>
<td>Dilaudid® 2mg Tablet</td>
<td>Hydrocodone HCl</td>
<td>Abbott Labs</td>
<td>Chicago, IL</td>
<td>60064</td>
</tr>
<tr>
<td>0074-2415-12</td>
<td>Dilaudid® 2mg Tablet</td>
<td>Hydrocodone HCl</td>
<td>Abbott Labs</td>
<td>Chicago, IL</td>
<td>60064</td>
</tr>
<tr>
<td>0074-2415-12</td>
<td>Dilaudid® 2mg Tablet</td>
<td>Hydrocodone HCl</td>
<td>Abbott Labs</td>
<td>Chicago, IL</td>
<td>60064</td>
</tr>
<tr>
<td>0074-2415-12</td>
<td>Dilaudid® 2mg Tablet</td>
<td>Hydrocodone HCl</td>
<td>Abbott Labs</td>
<td>Chicago, IL</td>
<td>60064</td>
</tr>
<tr>
<td>0074-2415-12</td>
<td>Dilaudid® 2mg Tablet</td>
<td>Hydrocodone HCl</td>
<td>Abbott Labs</td>
<td>Chicago, IL</td>
<td>60064</td>
</tr>
<tr>
<td>0074-2415-12</td>
<td>Dilaudid® 2mg Tablet</td>
<td>Hydrocodone HCl</td>
<td>Abbott Labs</td>
<td>Chicago, IL</td>
<td>60064</td>
</tr>
<tr>
<td>0074-2415-12</td>
<td>Dilaudid® 2mg Tablet</td>
<td>Hydrocodone HCl</td>
<td>Abbott Labs</td>
<td>Chicago, IL</td>
<td>60064</td>
</tr>
</tbody>
</table>

98-6146-R2
Dilaudid'®
Hydromorphone HCI
4mg Tablet
Protect from light.
Rx only
Abbott La. N. Chicago, IL
U.S.A.
Each tablet contains:

Hydromorphone HCl .......... 2 mg

Usual adult dose: See package insert.

Storage: Store at 25°C (77°F); excursions permitted to 15°–30°C (59°–86°F) See USP Controlled Room Temperature. Protect from light.

Tamper-Evident: Do not accept if sealed blister unit has been broken or opened.

See back panel for lot number and expiration date.

THIS PACKAGE FOR HOUSEHOLDS WITHOUT YOUNG CHILDREN.

Without Young Children.
THIS PACKAGE FOR HOUSEHOLDS WITHOUT YOUNG CHILDREN.

Each tablet contains:

hydromorphone HCl 4 mg

Usual adult dose: See package insert.

Storage: Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) (See USP Controlled Room Temperature). Protect from light.

Tamper-Evident: Do not accept if sealed blister unit has been broken or opened. See back panel for lot number and expiration date.

THIS PACKAGE FOR HOUSEHOLDS WITHOUT YOUNG CHILDREN.